Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant Acinetobacter baumannii

2021/03/09 by Sazlyna Mohd Sazlly Lim, Aaron J. Heffernan, Jason A. Roberts +1 · 3 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Antibiotics Pharmacokinetics and Efficacy #Antibiotic Resistance in Bacteria #Pneumonia and Respiratory Infections

paper · doi:10.1128/aac.02472-20

Abstract

Due to limited treatment options for carbapenem-resistant Acinetobacter baumannii (CR-AB) infections, antibiotic combinations are now considered potential treatments for CR-AB. This study aimed to explore the utility of fosfomycin-sulbactam combination (FOS/SUL) therapy against CR-AB isolates.

Citations

• Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies

Cited by

• Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremia
• Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review
• Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review

Related

• Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review
• Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
• Sulbactam for carbapenem-resistant Acinetobacter baumannii infections: a literature review
• Comparative in vitro activity of sulbactam with avibactam or durlobactam against carbapenem-resistant Acinetobacter baumannii
• The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection